These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 3093387

  • 1. [In vitro activity of new quinolones against nonfermenters and references to sensitivity tests].
    Grimm H.
    Infection; 1986; 14 Suppl 3():S191-5. PubMed ID: 3093387
    [Abstract] [Full Text] [Related]

  • 2. [In vitro activity of seven gyrase inhibitors of a group of heterocyclic carbonic acids against nonfermenting gram negative rods (nonfermenters)].
    Grimm H.
    Arzneimittelforschung; 1985; 35(3):570-2. PubMed ID: 2986655
    [Abstract] [Full Text] [Related]

  • 3. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
    Arpi M, Gahrn-Hansen B, Søgaard P, Bentzon MW.
    Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):141-6. PubMed ID: 3473910
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In-vitro selection of bacteria resistant to the 4-quinolone agents.
    Limb DI, Dabbs DJ, Spencer RC.
    J Antimicrob Chemother; 1987 Jan; 19(1):65-71. PubMed ID: 3470281
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P.
    Infection; 1986 Jan; 14(3):142-4. PubMed ID: 2942489
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R, Michéa-Hamzehpour M, Pechère JC.
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [In vitro antibacterial activity of new derivatives of pyridonecarboxylic acid, norfloxacin, ofloxacin, enoxacin and ciprofloxacin, against Vibrio cholerae O-1].
    Matsushita S, Yamada S, Kudoh Y, Ohashi M.
    Kansenshogaku Zasshi; 1987 Mar; 61(3):292-6. PubMed ID: 3112282
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
    Berlin OG, Young LS, Bruckner DA.
    J Antimicrob Chemother; 1987 May; 19(5):611-5. PubMed ID: 3112095
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
    Floyd-Reising SA, Kelley SG, Hindler JA, Young LS.
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):301-6. PubMed ID: 3472704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.